Expression of Flt-1 and Flk-1 receptors for vascular endothelial growth factor on tumor cells as a new prognostic criterion for locally advanced breast cancer
Expression of Flt-1 and Flk-1 receptors for vascular endothelial growth factor on tumor cells as a new prognostic criterion for locally advanced breast cancer
复制标题
DOI：
10.1023/a:1024975627843
复制
发表时间：
2003-05-01
影响因子：
0.7
通讯作者：
Lichinitser, MR
中科院分区：
文献类型：
--
作者：
Zhukova, LG;Zhukov, NV;Lichinitser, MR
我们研究了Flt-1和Flk-1受体在83例局部晚期乳腺癌患者新辅助化疗后肿瘤细胞上的表达。平均观察期为32.3个月。Flt-（1+）和Flt-（1-）患者的中位无复发生存期分别为55和32个月（p=0.0064）。Flt-（1-）和Flt-（1+）患者的总生存期分别为45和67.6个月（P=0.014）。Flk-（1+）和Flk-（1-）患者的平均无复发生存期分别为40.8和60.9个月（p=0.035）。VEGF的表达无预后价值。我们的研究结果表明，在接受新辅助化疗的乳腺癌细胞上Flk-1的过表达与不良预后相关。相比之下，Flt-1的过表达改善了存活率。
We studied expression of Flt-1 and Flk-1 receptors on tumor cells obtained from 83 patients with locally advanced breast cancer after neoadjuvant chemotherapy. The mean period of observations was 32.3 months. The median recurrence-free survival periods for Flt-(1+) and Flt-(1-) patients were 55 and 32 months, respectively (p=0.0064). The overall survival periods for Flt-(1-) and Flt-(1+) patients were 45 and 67.6 months, respectively (P=0.014). The mean recurrence-free survival periods for Flk-(1+) and Flk-(1-) patients were 40.8 and 60.9 months, respectively (p=0.035). Expression of VEGF had no prognostic value. Our results show that overexpression of Flk-1 on breast cancer cells in patients receiving neoadjuvant chemotherapy is associated with a poor prognosis. By contrast, overexpression of Flt-1 improves survival.